Market Overview:
The global benign prostate hyperplasia drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of benign prostate hyperplasia, rising geriatric population, and technological advancements in the field of benign prostate hyperplasia drugs. Based on type, the global benign prostate hyperplasia drugs market is segmented into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. The alpha blocker segment is expected to hold a dominant share in the global market during the forecast period owing to its high usage rates for treating symptoms associated with BPH. Based on application, the hospital segment is estimated to account for a major share of the global market during 2018–2030 owing to increased awareness about BPH and its treatment options among patients across regions.
Product Definition:
Benign prostate hyperplasia (BPH) is an enlargement of the prostate gland. The cause of BPH is not known, but it may be related to changes in male sex hormones as men age. BPH can cause problems with urination, such as difficulty starting or stopping the flow of urine, a weak urinary stream, and a need to urinate often or urgently (including during the night). Benign prostate hyperplasia drugs are medications used to treat symptoms of benign prostatic hyperplasia.
Alpha Blocker:
Alpha blockers are used to treat prostate gland enlargement. They work by decreasing the activity of the hormone known as “alpha” which is responsible for muscle contractions within the prostate gland. The drug works by relaxing or blocking some of the nerve cells in the brain that are connected to muscles near to urine bladder and also blocks some of those signals get transmitted back to trigger a full urinary stream.
5-Alpha Reductase Inhibitor:
5-ALPHA REDUCTASE INHIBITOR is an oral drug that decreases levels of prostate-specific antigen (PSA) in the blood. It works by decreasing the conversion of testosterone to 5-alpha reductase, which leads to lower production of dihydrotestosterone (DHT). Lowering DHT levels reduces prostate growth and may help treat or prevent BPH.
Application Insights:
The other application segment held the largest share of over 70.0% in 2017. The growth can be attributed to an increase in the number of patients suffering from BPH at a global level, which has resulted in increased demand for drugs treating this condition. In addition, favorable reimbursement policies may also have contributed to market growth during recent years.
Clinic and hospital are estimated to be the fastest-growing segments owing to increasing awareness about BPH and its treatment options among both healthcare professionals and patients worldwide.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of major players, high disease prevalence, and availability of effective treatment in this region. Moreover, increasing government funding for research & development activities is also expected to drive growth during the forecast period. For instance, as per a press release by U.S.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income and growing target population base especially in India and China; which are among countries with a high incidence rate for BPH/BPHC drugs such as Doxazosin mesylate or Terazosin hydrochloride or both combination products such as Cardura XL).
Growth Factors:
- Increasing prevalence of benign prostate hyperplasia (BPH) due to aging population
- Growing demand for minimally invasive procedures for the treatment of BPH
- Rising awareness about the available treatment options for BPH
- Technological advancements in the field of urology that are helping to improve the diagnosis and treatment of BPH
- increasing healthcare expenditure by governments and private players
Scope Of The Report
Report Attributes
Report Details
Report Title
Benign Prostate Hyperplasia Drugs Market Research Report
By Type
Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others
By Application
Hospital, Clinic, Other
By Companies
Sanofi, Coloplast, Pfizer, Merck, GlaxoSmithKline, Eli Lilly and Company, Abbott Laboratories, Teva Pharmaceuticals, Allergan, Boehringer Ingelheim
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
213
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Benign Prostate Hyperplasia Drugs Market Report Segments:
The global Benign Prostate Hyperplasia Drugs market is segmented on the basis of:
Types
Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Coloplast
- Pfizer
- Merck
- GlaxoSmithKline
- Eli Lilly and Company
- Abbott Laboratories
- Teva Pharmaceuticals
- Allergan
- Boehringer Ingelheim
Highlights of The Benign Prostate Hyperplasia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alpha Blocker
- 5-Alpha Reductase Inhibitor
- Phosphodiesterase-5 Inhibitor
- Others
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Benign Prostate Hyperplasia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Benign prostate hyperplasia drugs are medications used to treat benign prostatic hyperplasia (BPH). These drugs work by shrinking the size of the prostate.
Some of the key players operating in the benign prostate hyperplasia drugs market are Sanofi, Coloplast, Pfizer, Merck, GlaxoSmithKline, Eli Lilly and Company, Abbott Laboratories, Teva Pharmaceuticals, Allergan, Boehringer Ingelheim.
The benign prostate hyperplasia drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Benign Prostate Hyperplasia Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Benign Prostate Hyperplasia Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Benign Prostate Hyperplasia Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Benign Prostate Hyperplasia Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Benign Prostate Hyperplasia Drugs Market Size & Forecast, 2018-2028
4.5.1 Benign Prostate Hyperplasia Drugs Market Size and Y-o-Y Growth
4.5.2 Benign Prostate Hyperplasia Drugs Market Absolute $ Opportunity
Chapter 5 Global Benign Prostate Hyperplasia Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Benign Prostate Hyperplasia Drugs Market Size Forecast by Type
5.2.1 Alpha Blocker
5.2.2 5-Alpha Reductase Inhibitor
5.2.3 Phosphodiesterase-5 Inhibitor
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Benign Prostate Hyperplasia Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Benign Prostate Hyperplasia Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Benign Prostate Hyperplasia Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Benign Prostate Hyperplasia Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Benign Prostate Hyperplasia Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Benign Prostate Hyperplasia Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Benign Prostate Hyperplasia Drugs Market Size Forecast by Type
9.6.1 Alpha Blocker
9.6.2 5-Alpha Reductase Inhibitor
9.6.3 Phosphodiesterase-5 Inhibitor
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Benign Prostate Hyperplasia Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Benign Prostate Hyperplasia Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Benign Prostate Hyperplasia Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Benign Prostate Hyperplasia Drugs Market Size Forecast by Type
10.6.1 Alpha Blocker
10.6.2 5-Alpha Reductase Inhibitor
10.6.3 Phosphodiesterase-5 Inhibitor
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Benign Prostate Hyperplasia Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Benign Prostate Hyperplasia Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Benign Prostate Hyperplasia Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Benign Prostate Hyperplasia Drugs Market Size Forecast by Type
11.6.1 Alpha Blocker
11.6.2 5-Alpha Reductase Inhibitor
11.6.3 Phosphodiesterase-5 Inhibitor
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Benign Prostate Hyperplasia Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Benign Prostate Hyperplasia Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Benign Prostate Hyperplasia Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Benign Prostate Hyperplasia Drugs Market Size Forecast by Type
12.6.1 Alpha Blocker
12.6.2 5-Alpha Reductase Inhibitor
12.6.3 Phosphodiesterase-5 Inhibitor
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Benign Prostate Hyperplasia Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Benign Prostate Hyperplasia Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Benign Prostate Hyperplasia Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Benign Prostate Hyperplasia Drugs Market Size Forecast by Type
13.6.1 Alpha Blocker
13.6.2 5-Alpha Reductase Inhibitor
13.6.3 Phosphodiesterase-5 Inhibitor
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Benign Prostate Hyperplasia Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Benign Prostate Hyperplasia Drugs Market: Competitive Dashboard
14.2 Global Benign Prostate Hyperplasia Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Coloplast
14.3.3 Pfizer
14.3.4 Merck
14.3.5 GlaxoSmithKline
14.3.6 Eli Lilly and Company
14.3.7 Abbott Laboratories
14.3.8 Teva Pharmaceuticals
14.3.9 Allergan
14.3.10 Boehringer Ingelheim
